Applications of Generative AI in Drugs Development and Materials Discovery: IP Considerations
This article explores how generative AI (genAI) is revolutionizing drug development and materials discovery by accelerating innovation and reducing costs.
This article explores how generative AI (genAI) is revolutionizing drug development and materials discovery by accelerating innovation and reducing costs.
The "malice" in malicious patent litigation is primarily evident in the claimant's "awareness" that their lawsuit lacks a legitimate basis in rights or factual grounds. Determining this subjective state should be based on the facts of the case and established principles.
The study considers all costs incurred throughout the innovation stage to the end of patent life. The findings suggest that the lifetime cost of a good patent can be minimized by a particular combination of the internal pass rate and the official grant rate.
A well-drafted and clear patent specification with precise and unambiguous technical terms, structured in a logical and consequential way, might represent a competitive advantage for the Applicant and increase the chances of success in granting the European patent.
What should Chinese companies consider when expanding to Europe? The following article outlines important patenting tactics for successful market entry. Patenting in Europe differs from patenting in China. Some aspects should be taken into account already before entering Europe.